News and Trends 3 Jun 2017 The Microscopic World of Bacteria Comes to Life with Sculpture Aimee Lax is a British sculptor that explores the bizarre world of microscopic life by making beautiful sculptures that magnify their tiny size. “There’s a whole world out there that we never see, but it’s all here, it’s all real,” says Aimee Lax. Her piece Bacteriophages was included in the permanent exhibition Invisible You – The […] June 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2017 Austrian Researchers build an improved Mini-Brain to support Psychiatry Researchers from Austria and the UK have made new advances in engineering brain-like structures. These lab-grown organoids mimic important functions of the real thing and could help improve understanding of mental illness and test new therapies. The Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna is a pioneer of brain […] June 2, 2017 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
Startup Scout 2 Jun 2017 This French Biotech Wants to Reinvent DC-based Immunotherapies This week we had the chance to visit both Grenoble and Liège, where the French-Belgian biotech hybrid PDC*line Pharma has its two headquarters. The company is progressing new types of immunotherapies based on dendritic cells (DCs). Mission: PDC*line Pharma emerged from an R&D program of the French Blood Bank (EFS, Etablissement Français du Sang), where […] June 2, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2017 Why Should we be Excited about the Emerging Microbiome Field? A panel of experts at Microbiome Invest in London discussed the unlimited applications of the microbiome and how emerging companies may have a big impact on healthcare. During the past 10 years, the role of bacterial populations within our own organism has been studied, revealing a huge potential to develop new types of therapeutics. “The microbiome represents a […] June 1, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jun 2017 Next-Gen Drug Conjugates Bank €46M in Series B with American Investors Bicycle Therapeutics has closed a massive fundraising round, raking in £40M (€46M) from American investors to launch clinical trials. Bicycle Therapeutics, the most recent company founded by the legendary academic-entrepreneur Greg Winter, is making a name for itself as a money magnet. Hot on the heels of a €1B deal with AstraZeneca last fall, the biotech […] June 1, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 Recruitment in Biotech is Broken, Here’s How to Fix it How can changing the way your company hires, improve your business and result in better employees? Zocket brings a fresh approach to a long-standing challenge, to a systemic problem in our industry. There are multiple challenges when hiring new talent in a growing biotech. Given the rapid growth of the industry and the worldwide shortage […] May 31, 2017 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 Swiss Biotech raises €10M to Target Elusive Protein Interactions in Cancer Inthera Bioscience has raised €9.6M in Series A to complete preclinical phase of its lead cancer program and expand its pipeline. Inthera Bioscience, located in Zurich, has closed a €9.6M (CHF 10.5M) Series A round led by Merck Ventures and backed by Novo Seeds and BioMedical Ventures, as well as a private investor. Members of Novo Seeds and […] May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 German Biotech Enters the Clinic with Next-Generation Antibody for AML Synimmune has hit the clinic with a first-in-human study of its Fc-optimized antibody FlySyn to treat patients with acute myeloid leukemia (AML). The German biotech Synimmune is developing next-generation anti-cancer antibodies to treat rare blood cancers. Its lead asset, FlySyn, is an antibody directed against the human fms-like tyrosine kinase 3 (FLT3) for the treatment of patients with […] May 31, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 31 May 2017 Swiss Biotech raises €9M to Treat Sudden Hearing Loss in Phase III Strekin has closed a Series C financing round that will fund the progression of its lead candidate for hearing loss to Phase III. Based in Basel, Strekin focuses on repurposing existing drugs by discovering new mechanisms of action. The company has now received €9.2M (CHF 10M) in Series C to fund the company’s activity until 2019 […] May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 31 May 2017 Poll: Academia, Biotech or Another Career? How Industry Leaders Decided Inspired by Philip’s interview with Patrick Baeuerle, who traversed academia, entrepreneurship and finance, I collected thoughts from biotech leaders on choosing a direction. Morten Sommer Professor of Systems Biology, TU Denmark Founder of Biosyntia, AntibioTx, Microlytic There’s a lot of freedom in academia that allows you to explore things that don’t have to be immediately […] May 31, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2017 Swiss Researchers get to the Genetic Bottom of Kidney Cancer Researchers from the University of Zurich have established a new mouse model of kidney cancer that could further our understanding of this deadly disease. Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer and in roughly half of the patients with this disease the tumor develops metastasis and can’t be […] May 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 30 May 2017 FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford The FDA has handed out a Fast Track Designation to AMO Pharma for its key asset AMO-02 to treat congenital myotonic dystrophy. The British-American biotech hybrid AMO Pharma is advancing a small pipeline of drugs for rare genetic disorders. The biotech, which is backed by famous UK Investor Neil Woodford, is currently pushing its lead candidate […] May 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email